- Home
- OR vs IMVT Comparison
OR vs IMVT Comparison
Compare OR & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OR
- IMVT
- Stock Information
- Founded
- OR 2014
- IMVT N/A
- Country
- OR Canada
- IMVT United States
- Employees
- OR N/A
- IMVT N/A
- Industry
- OR Precious Metals
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OR Basic Materials
- IMVT Health Care
- Exchange
- OR Nasdaq
- IMVT Nasdaq
- Market Cap
- OR 3.7B
- IMVT 3.4B
- IPO Year
- OR N/A
- IMVT N/A
- Fundamental
- Price
- OR $21.02
- IMVT $17.09
- Analyst Decision
- OR Buy
- IMVT Strong Buy
- Analyst Count
- OR 2
- IMVT 11
- Target Price
- OR $22.00
- IMVT $44.13
- AVG Volume (30 Days)
- OR 1.0M
- IMVT 1.9M
- Earning Date
- OR 05-07-2025
- IMVT 02-06-2025
- Dividend Yield
- OR 0.89%
- IMVT N/A
- EPS Growth
- OR N/A
- IMVT N/A
- EPS
- OR 0.09
- IMVT N/A
- Revenue
- OR $191,157,000.00
- IMVT N/A
- Revenue This Year
- OR $59.27
- IMVT $108.88
- Revenue Next Year
- OR $5.45
- IMVT N/A
- P/E Ratio
- OR $240.73
- IMVT N/A
- Revenue Growth
- OR 4.33
- IMVT N/A
- 52 Week Low
- OR $15.12
- IMVT $17.01
- 52 Week High
- OR $21.34
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- OR 63.42
- IMVT 35.37
- Support Level
- OR $20.67
- IMVT $17.49
- Resistance Level
- OR $21.28
- IMVT $18.96
- Average True Range (ATR)
- OR 0.58
- IMVT 1.22
- MACD
- OR 0.17
- IMVT -0.10
- Stochastic Oscillator
- OR 87.38
- IMVT 1.43
About OR Osisko Gold Royalties Ltd
Osisko Gold Royalties Ltd is engaged in the business of acquiring and managing precious metal and other high-quality royalties, streams and similar interests. The Company owns a portfolio of royalties, streams, offtakes, options on royalty/stream financings and exclusive rights to participate in future royalty/stream financings on various projects. Geographically, it generates majority of its income from North America and also generates some portions of income from South America, Australia, Africa and Europe.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).